## **Special Issue**

# Targeting The Nuclear Factor Kappa-B (NF-⊠B) Pathway for Drug Discovery

## Message from the Guest Editor

The dysregulation of IKK/NF-kB has been shown to be associated with inflammatory and autoimmune diseases, given the fact that the IKK/NF-kB pathways play a central role in immune and inflammatory responses. In addition, IKK/NF-kB-mediated inflammation is essential for the pathogenesis of other common human diseases such as cancer, diabetes, cardiac dysfunction and aging.

Since the direct pharmacologic inhibition of IKKb kinase activity has limited value in disease treatment, targeting NEMO-IKKb interaction or other protein–protein interaction interfaces to attenuate excessive IKKb activation under pathological conditions is considered as a promising strategy to develop novel therapeutics. In this special Issue, we invite authors in this field to report their original research discoveries pertaining to novel therapeutic approaches for targeting IKK. We are especially interested in novel research strategies that target allosteric sites and other protein–protein interaction interfaces, thereby inhibiting IKK activation, which would avoid severe side effects due to induced apoptosis and IL-1b secretion.

#### **Guest Editor**

Dr. Guozhou Xu

Department of Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC 27695, USA

## Deadline for manuscript submissions

closed (25 April 2025)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/195741

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

